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Background: The ubiquitin proteasome system (UPS) is one of the main proteolytical pathways in eukaryotic cells
and plays an essential role in key cellular processes such as cell cycle, stress response, signal transduction, and
transcriptional regulation. Many components of this pathway have been implicated in diverse pathologies including
cancer, neurodegeneration and infectious diseases, such as malaria. The success of proteasome inhibitors in clinical
trials underlines the potential of the UPS in drug discovery.
Methods: Plasmodium falciparum, the malaria causative pathogen, has been used to develop two assays that allow
the quantification of the parasite protein ubiquitylation levels in a high-throughput format that can be used to find
new UPS inhibitors.
Results: In both assays tandem ubiquitin binding entities (TUBEs), also known as ubiquitin traps, have been used to
capture ubiquitylated proteins from cell lysates. The primary assay is based on AlphaLISA technology, and the
orthogonal secondary assay relies on a dissociation-enhanced lanthanide fluorescent immunoassay (DELFIA) system.
A panel of well-known proteasome inhibitors has been used to validate both technologies. An excellent correlation
was obtained between these biochemical assays and the standard whole cell assay that measures parasite growth
inhibition.
Conclusions: The two assays presented can be used in a high-throughput format to find new UPS inhibitors for P.
falciparum and could help to identify new targets within this system. This methodology is also applicable to other
cellular contexts or pathologies.
Keywords: Plasmodium falciparum, Malaria, Ubiquitin proteasome system, High-throughput screening, Tandem
ubiquitin binding entities, Cellular assay, Drug discoveryBackground
Plasmodium falciparum is responsible for the most se-
vere form of human malaria. Spreading resistance to
current treatments urges the need for new medicines with
novel modes of action. After decades pursuing target-
based programmes, the focus now is on phenotypic* Correspondence: concha.cid@gsk.com; msrodriguez@inbiomed.org
2Centro de Investigación Básica, GlaxoSmithKline, Santiago Grisolía 4, 28760
Tres Cantos, Madrid, Spain
3Ubiquitylation and Cancer Molecular Biology, Inbiomed, Mikeletegi 81,
20009 San Sebastian, Spain
Full list of author information is available at the end of the article
© 2015 Mata-Cantero et al.; licensee BioMed C
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.screenings, as the knowledge of the biology of the parasite
is limited and, at least in theory, inhibitors of any essential
pathway of the parasite could be found. One such essen-
tial pathway is the ubiquitin proteasome system (UPS)
which consists in a covalent, post-translational modifica-
tion that orchestrates the function and turnover of numer-
ous cellular proteins and regulates many essential cellular
processes, such as cell cycle progression, transcription,
endocytosis, DNA repair, apoptosis, signal transduction,
differentiation, cellular stress, and protein trafficking. Al-
terations of the UPS have been implicated in a largeentral. This is an Open Access article distributed under the terms of the Creative
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degenerative and immunological disorders, and also infec-
tious diseases. Therefore, the UPS has become one of the
most promising targets for drug development [1].
The UPS consists of multiple enzymes and cofactors
that regulate the attachment/detachment of ubiquitin to
target proteins before being exposed to the 26S prote-
asome. Ubiquitin is a highly conserved protein among
eukaryotes showing only few amino acid differences be-
tween mammalian and yeast versions [2]. The protein
modification process, also known as conjugation, re-
quires three sequential steps that start with the activa-
tion of the C-terminal glycine residue of the ubiquitin by
an ubiquitin-activating enzyme (E1), which forms a thio-
lester linkage with ubiquitin. This activated ubiquitin is
transferred to an ubiquitin-conjugating enzyme (E2) and
then to an ubiquitin-ligase (E3) that specifically interacts
with the protein substrate. The C-terminal glycine of
ubiquitin is attached to an amino group of a lysine
present in the substrate. Additionally, ubiquitin has
seven active lysines that can accept ubiquitin moieties
generating different types of polyubiquitin chains. Some
polyubiquitin chains have been associated with specific
cellular functions. For example, K63 chains that activate
signalling cascades or K48 and K11 chains that are
linked to protein degradation by the proteasome. The
process can be reverted by the action of deubiquitylating
enzymes (DUBs) that are responsible for the dynamic
equilibrium of the system.
The 26S proteasome is a multi-sub-unit complex
formed by a 20S core particle, responsible for the cata-
lytic activity, and by regulatory 19S particles flanking
each end of the core to control the entry of ubiquitylated
proteins. The 20S core consists of four heptameric rings,
the two outer rings are formed by alpha sub-units and
the two inner rings are composed of beta sub-units. β1,
β2 and β5 sub-units are responsible for the peptidyl-
glutamyl peptide-hydrolyzing (PHGH), the trypsin and
the chymotrypsin-like activities of the proteasome, re-
spectively [3].
Several UPS components have been considered as
druggable targets since some of them are directly in-
volved in different human diseases. Proteasome was the
first successful target within the UPS. The proteasome
inhibitor, bortezomib reached clinical phases for the
treatment of various types of cancer. Since its approval
for the treatment of multiple myeloma and mantle cell
lymphoma in 2003, another four inhibitors of the UPS
are in clinical trials and seven more are in preclinical
studies [4-7]. The efficacy and limited toxicity of these
inhibitors are based on the fact that rapidly dividing can-
cer cells are more sensitive than non-dividing ones sug-
gesting that very active processes will be better blocked
by UPS inhibitors.Plasmodium falciparum divides rapidly during its
intra-erythrocytic cycle (see Figure 1A), fulfilling the cri-
teria to be targeted by a UPS inhibitor. Moreover, mul-
tiple evidence indicates that the UPS is involved in the
parasite cell cycle progression and protein quality con-
trol [8,9]. Even though there is a conserved sequence
homology between the parasite and human proteasome
proteins, there is space for selectivity not only in the
proteasome but also at specific components of the UPS
such as E3 ligases and DUBs [10-12]. Targeting P. falcip-
arum UPS can provide novel modes of action to over-
come the emerging resistance to current treatments, as
already demonstrated in vitro [13]. Indeed, proteasome
inhibitors can efficiently inhibit P. falciparum-resistant
strains at various stages of the cycle in the nanomolar
range and with limited toxicity to humans [13-15]. New
inhibitors targeting specifically the parasite UPS are de-
sirable [16] to reduce possible side effects.
Thus, the aim is to develop assays that can detect in-
hibitors of any of the steps involved in UPS, with a high
throughput. Even though there are some assays pub-
lished that measure UPS activity, they are based on
quantifying proteasome activity, either biochemically or
in cell-based assays using engineered strains. These as-
says give a large number of false positives and negatives
and can be biased by a different homeostasis of the
modified cell [17-21]. The effect of compounds on the
whole UPS can also be assessed by measuring the total
level of ubiquitylated proteins that are present in cell ly-
sates after treatment. Proteasome inhibition causes an
accumulation of ubiquitylated proteins that can be ana-
lysed by Western blot [22]. However this method is
costly and time consuming and hence is not suitable for
high-throughput screening (HTS). Assays with higher
throughput using TR-FRET and AlphaLISA in combin-
ation [23,24] with tandem ubiquitin binding entities
(TUBEs) [25], have also been published, but they are
target-based approaches that make use of recombinant
proteins. Moreover, they are limited to a precise activity
within the UPS, therefore previous knowledge about the
target is required.
Here, the development of two cellular assays to quan-
tify the total pool of ubiquitylated proteins in P. falcip-
arum cell lysates is presented, which can be used as
primary and secondary assays in a HTS campaign to find
inhibitors of the UPS as a whole, that is, inhibitors of
any step that can significantly alter the level of ubiquity-
lated proteins. These assays are based on the use of
TUBEs, which are tandem ubiquitin-associated domains
(UBA) fused to a glutathione S-transferase (GST) or bio-
tin tag that allow the purification of captured ubiquitin
conjugates in native conditions after cell lysis. The tan-
dem disposition of UBA domains increases the affinity
for ubiquitin chains and also protects ubiquitylated
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somal degradation [25-27].
The first assay developed is a homogeneous assay
based on the AlphaLISA technology that can be used as
a primary test to screen any compound collection to
identify molecules that putatively alter the levels of ubi-
quitylated proteins. The second technique is a heteroge-
neous dissociation-enhanced lanthanide fluorescent
immunoassay (DELFIA) assay that can be useful to con-
firm the positive compounds found in the primary assay,
and hence discard false-positive compounds associated
with AlphaLISA technology. This heterogeneous assay
requires washing steps, thus increasing the time of ma-
nipulation and results deviation and has higher associ-
ated costs when used for HTS. However, the advantage
is the reduction of background interference by com-
pounds and biological components of the assay. The
DELFIA assay could also be used independently as a
primary assay during hit optimization process to assess
the potency of compounds in dose–response experi-
ments. Assays described here have been validated using
a panel of well-known proteasome inhibitors and could
be used to quantify the UPS activity in cells or to run
HTS campaigns in order to find selective inhibitors of
this pathway. These universal methods have been set up
using P. falciparum-infected red blood cells (iRBCs) as
the biological system to identify compounds that alter
UPS, but conditions could be adapted easily to other cell
types and pathologies or to study and/or find specific
inhibitors of particular components of the UPS.
Methods
Reagents
Hypoxanthine, sorbitol, percoll, MG132, Epoxomicin,
Lactacystin, Clasto-lactacystin β-lactone, Gliotoxin,
MG115, EDTA, sodium phosphate dibasic, monoso-
dium phosphate, Tris HCl, sodium chloride, Tween-20,
sodium pyrophosphate, glycerol-2-phosphate, saponin,
bovine serum albumin (BSA), dithiothreitol (DTT) and
phenylmethylsulphonyl fluoride (PMSF) were pur-
chased from Sigma. Glutathione acceptor beads, pro-
tein A donor beads, DELFIA enhancement solution and
DELFIA secondary antibody (Eu-N1 rabbit Anti-
mouse-IgG) came from Perkin Elmer. NP-40 was pur-
chased from Calbiochem, sodium fluoride from Pan-
reac, antibody anti-ubiquitin P4D1 from Santacruz,
deubiquitylases inhibitor PR-619 came from Merck,
complete mini EDTA protease inhibitor cocktail from
Roche, antibody anti-ubiquitin FK2 from Enzo, biotin-
TUBEs from Life sensor, RPMI 1640 medium from
Gibco, AlbuMAX II from Invitrogen, bortezomib from
Selleckchem, enhanced chemiluminescence (ECL) from
GE Healthcare and PBS from Oxoid. Atovaquone was
prepared in house.Plasmodium falciparum cultures
All experiments were performed using P. falciparum
strain 3D7A obtained from the Malaria Research and
Reference Reagent Resource (MR4) [28]. Parasites were
maintained in culture in T150 flasks in a 5% CO2,
90% N2 and 5% O2 atmosphere, using RPMI 1640
medium supplemented with 5% AlbuMAX II, 150 μM
hypoxanthine and fresh red blood cells (uRBCs) accord-
ing to the methods previously described [29,30]. uRBCs
were obtained from the Spanish Red Cross Blood Bank.
GST-TUBEs expression and purification
TUBEs tagged with GST were expressed in Escherichia
coli C41 (DE3) as previously reported [25], although they
are also available from Lifesensors. Expression of TUBEs
was induced with 1 mM IPTG for 6 hrs at 20°C. Bacteria
were lysed by sonication in PBS with 1% triton X-100
and 2 mM benzamidine and lysates were clarified by
centrifugation at 20,000 rpm for 2 hrs at 4°C. TUBEs
were purified by standard glutathione agarose beads fol-
lowing manufacturer instructions. Briefly, lysate was in-
cubated with glutathione agarose beads for 2 hrs at 4°C
and then these beads were washed with 1% triton X-100
in PBS. Recombinant TUBEs were eluted with 10 mM
glutathione in 50 mM Tris–HCl pH 9.5. After a buffer
exchange to PBS (Amicon ultra centrifugal filter cut off
3 kDa) protein concentration was determined by absorb-
ance at 280 nm.
Western blot analysis
Plasmodium falciparum cultures were synchronized
with 5% w/v sorbitol enriching iRBCs in ring stage, and
maintained for three days at 0.8% haematocrit and 2%
parasitaemia as previously described [30]. Haematocrit is
defined as the volume percentage of RBCs and parasit-
aemia is the percentage of iRBCs in the culture. Then, a
new synchronization cycle was done through a 70% per-
coll gradient (v/v) isolating iRBCs highly synchronized in
schizont stage [30]. Culture was adjusted to 5% parasit-
aemia and 1% haematocrit with fresh uRBCs and grown
for an extra day. Then, iRBCs were treated with prote-
asome inhibitors MG132 (1.15 μM) or Epoxomicin
(0.26 μM) and incubated for 1 hr at 37°C at 20 times the
IC50 that causes the parasite growth inhibition. Samples
were taken at three different time points; time zero
(rings), 14 hrs (trophozoites) and 24 hrs (schizonts).
Atovaquone, an anti-malarial drug, was used at 0.02 μM
as a negative control since it does not target the UPS
system. Cultures, without any treatment, were also taken
to assess the basal levels of ubiquitylated proteins. Plas-
modium falciparum cultures were pelleted by centrifuga-
tion at 600 g for 5 mins and frozen at −80°C for at least
24 hrs. Then, pellets containing the parasites were
treated with 0.1% w/v saponin in PBS for 5 min at 4°C.
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washed three times with cold PBS to remove haemoglo-
bin until the supernatant was clear. The cell pellets cor-
responding to purified parasites were resuspended in
lysis buffer (50 mM NaF, 5 mM tetra-sodium pyrophos-
phate, 10 mM β-glyceropyrophosphate, 1% NP-40,
2 mM EDTA, 20 mM Na2HPO4, 20 mM NaH2PO4,
1 mM PMSF and complete mini EDTA protease inhibi-
tor cocktail) and lysed with two cycles of sonication
(10 sec each). Lysates were cleared by centrifugation for
10 min at 14,000 rpm and 4°C and supernatant col-
lected. Protein amount was quantified by Bradford. For
each condition, equal amount of proteins were separated
by SDS-PAGE. Proteins were then transferred onto poly-
vinylidene difluoride (PVDF) membranes (Roche) and
incubated with anti-ubiquitin P4D1 antibody diluted
1:1,000 to analyse ubiquitylated proteins.
Plasmodium falciparum extracts for assay development
To set up the assays, P. falciparum parasites at schizont
stage were isolated from RBCs to remove haemoglobin
which causes interference in the AlphaLISA technology.
Plasmodium falciparum cultures were synchronized
with sorbitol and percoll as described in the previous
section. Cells were grown for two days at 1% haemato-
crit and 5% parasitaemia. Then, cultures enriched with
schizonts at 10% parasitaemia were treated for 1 hr with
the proteasome inhibitor MG132 at 1.15 μM or kept
without treatment as basal control, depending on each
experiment. iRBCs were centrifuged at 600 g for 5 min
and frozen at −80°C. Parasites were extracted with
0.1% w/v saponin, washed three times in PBS and then
lysed by sonication in lysis buffer (50 mM Tris pH 7.5,
5 mM EDTA, 150 mM NaCl 1% Tween 20, complete
mini-EDTA free anti-proteases, 1 mM PMSF, 50 μM
deubiquitylase inhibitor PR-619 (DUBI), a cell-
permeable broad spectrum inhibitor that does not affect
the proteasome activity and it is used to protect against
deubiquitylation processes in the lysis moment) as de-
scribed above, obtaining a clear parasite protein lysate
without haemoglobin. Lysates were then dispensed in
384-or 1,536-well plates to assess levels of ubiquitylated
proteins by AlphaLISA or DELFIA assays under different
conditions (see Results).
Purification of iRBCs with schizonts and treatment with
compounds
The developed assays were designed to use in vitro P.
falciparum iRBCs highly synchronized in schizonts fol-
lowing the protocol previously described [30]. Briefly, P.
falciparum cultures were synchronized using sorbitol
and percoll treatments as described above. Cultures ad-
justed to 5% parasitaemia and 1% haematocrit after per-
coll synchronization were grown for 48 hrs and thenpassed through magnetic MACs columns type CS (Mil-
tenyi biotec). These columns only retain RBCs that are
infected with mature forms of P. falciparum, enriching
the eluate with a parasitaemia of iRBCs in schizont stage
up to 98%. Cells were pelleted by centrifugation at 600 g
for 5 min and adjusted with supplemented RPMI 1640
medium to 0.4% haematocrit for AlphaLISA and 0.2%
haematocrit for DELFIA assay. Cultures were kept in the
incubator at 37°C for 1 hr and then dispensed into plates
containing proteasome inhibitors: 2 μL in 1,536-well
white plates (Greiner) containing 20 nL of compound
for AlphaLISA and 20 μL in 384-, flat-bottom, black
plates containing 200 nL of compound for DELFIA
assay. Proteasome inhibitors were dissolved in 100%
DMSO, being 1% the final DMSO concentration in the
assays. Plates with iRBCs and compounds were incu-
bated at 37°C for 1 hr and then frozen at −80°C.
TUBE-AlphaLISA assay
Assay was set up in 1,536-well white plate, in which
2 μL of each reagent were added per well and step,
reaching all together a final volume of 10 μL. Frozen
plates containing 2 μL of iRBCs and 20 nL of com-
pounds (as described in the previous section) were
thawed, to avoid deconjugation processes, in presence of
2 μL of lysis buffer containing TUBEs (50 mM Tris
pH 7.5, 5 mM EDTA, 150 mM NaCl, 1% Tween 20,
50 μM DUBI, complete mini-EDTA free anti-proteases,
1 mM PMSF and 25 μg/mL GST-TUBEs). Lysis was per-
formed by three fast freeze/thaw cycles (10 min each)
and then the plates were kept at room temperature for
1 hr to enable the efficient capture of ubiquitylated pro-
teins by the GST-TUBEs. Two μL of AlphaLISA GSH
acceptor beads at 0.1 μg/μL diluted in AlphaLISA assay
buffer (100 mM sodium phosphate buffer pH 7, 0.1%
BSA) with 7.5 mM DTT were added. Plates were sealed
and incubated for 4 hrs at 4°C to allow the binding of
GSH beads with the GST-TUBEs. Then, 2 μL of anti-
ubiquitin FK2 antibody (diluted 1:80 in AlphaLISA assay
buffer) was dispensed and incubated for 1 hr at 4°C in
darkness. Finally, 2 μL of protein A donor beads at
0.2 μg/μL (in assay buffer) were added and plates were
incubated in darkness at 4°C overnight, enabling the
binding of the FK2 antibody and the donor beads. The
levels of ubiquitylated proteins were determined by
measuring the light emission at 615 nm in the Envision
multilabel reader (Perkin Elmer) using the AlphaLISA
protocol.
TUBE-DELFIA assay
In a typical assay, the addition of each reagent was pre-
ceded by six washing steps with 100 μL of TBS-Tween
(50 mM Tris HCl, 2.7 mM KCl, 138 mM NaCl, 0.05%
Tween 20) to remove the unbound fraction. The day
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ner) was incubated overnight at 4°C with 20 μL of
1.5 ng/μL biotin-TUBEs in PBS to allow binding of the
TUBEs to the plate. Then, plates were washed with TBS-
Tween and 10 μL of lysis buffer (50 mM Tris pH 7.5,
5 mM EDTA, 150 mM NaCl, 1% Tween 20, 50 μM
DUBI, complete mini-EDTA free anti-proteases, 1 mM
PMSF) was added. The 384-plates prepared previously
(see above) that contained iRBCs incubated with com-
pounds were thawed and 10 μL of the culture was trans-
ferred to the streptavidin plates containing TUBEs and
lysis buffer. iRBCs lysis was performed applying three
freeze/thaw cycles (10 min each) and then these strepta-
vidin plates were incubated for 1 hr at room
temperature in a microtitre-plate shaker to favour the
capture of all the ubiquitylated proteins by the TUBEs.
After washing the plates to remove the unbound pro-
teins, 10 μL of antibody anti-ubiquitin FK2 diluted 1:200
in DELFIA assay buffer (50 mM Tris HCl 7.5, 20 μM
EDTA, 500 mM NaCl, 0.01% Tween 20 and 0.1% BSA)
was added and incubated for 1 hr at room temperature
under low shaking. Then plates were washed and an add-
itional incubation with 10 μL of DELFIA secondary anti-
body (diluted 1:200 in DELFIA assay buffer) was
performed for 1 hr, followed by the last washing cycles. Fi-
nally, 25 μL of the enhancement solution was added,
which causes the release of the europium. Plates were
then incubated for at least 15 min at room temperature
with shaking before reading. Fluorescence signal from
europium was recorded in the Envision plate reader using
a protocol for time-resolved fluorescence with excitation
at 340 nm and emission at 615 nm. The long fluorescence
lifetime of europium enables the use of time-resolved fluo-
rimetry to eliminate background interferences.
Data analysis
The effect of compounds was calculated taking as ref-
erence the basal level of ubiquitylated proteins in
iRBCs (control 1 = basal levels of ubiquitylated pro-
teins in cell lysates in 1% DMSO, in the absence of
compound). The increase in the levels of the ubiquity-
lated proteins was calculated using the stimulation
formula: % stimulation = 100*(sample/control 1), being
100% the basal levels without stimulation (control 1).
Compounds that inhibit the proteasome activity will
cause an increase in the levels of ubiquitylated pro-
teins, and hence an increase in the AlphaLISA or
DELFIA signals. Samples above the cut-off (calculated
as the average of control 1 plus three times its stand-
ard deviation) were considered positives. TIBCO Spot-
fire 3.2 software was used to perform this analysis.
In the dose response graphs, all curves were normal-
ized between 0 and 100% inhibition. Maximum levels of
ubiquitylated protein for each compound wereconsidered as 100% of UPS inhibition (B). Minimum
levels of ubiquitylated proteins (0%) were the basal levels
without any treatment (A). Data were calculated normal-
izing the raw counts with respect to the minimum (A)
and maximum (B) counts per compound (% inh = 100 –
(100 * (sample – B)/(A – B)). pIC50s (−log molar IC50)
were calculated and represented using GraFit 5 (Eritha-
cus Software, Horley, Surrey, UK).
Results
Assessment of the levels of ubiquitylated proteins at
different parasite stages
Plasmodium falciparum intra-erythrocytic cycle, which in-
cludes rings, trophozoites and schizonts stages (Figure 1A)
was used to set up the assays as it is related with its patho-
genesis and is the primary target of anti-malarial drug de-
velopment. Total amount of ubiquitylated proteins at each
stage of the intra-erythrocytic cycle was analysed by
Western blot using anti-ubiquitin P4D1 antibody.
Figure 1B shows the levels of ubiquitylated proteins in
parasite extracts (see Methods – “Plasmodium falcip-
arum extracts for assay development) during ring,
trophozoite and schizont stages. The levels of ubiquity-
lated proteins increased along the cycle, reaching the
highest concentration in schizonts in accordance with
previously reported data [9].
To determine the stage containing the largest accumu-
lation of ubiquitylated proteins after treatment with a
UPS inhibitor, two different proteasome inhibitors were
used: the well-known MG132 and epoxomicin. iRBCs
with P. falciparum at different stages were treated for
1 hr with these proteasome inhibitors. Atovaquone was
used as negative control, as its mode of action is not re-
lated to UPS. Plasmodium falciparum proteins were iso-
lated and then quantified by Bradford to normalize the
amount of proteins loaded in the gel. As expected, ato-
vaquone did not change the amount of ubiquitylated
proteins while MG132 and epoxomicin treatments re-
sulted in an accumulation of ubiquitylated proteins at
schizont stage of 1.8 and 1.5 times, respectively, when
compared to the basal levels (Figure 1C), correlating
with previously published data [9]. Taking into account
these results, parasites at schizont stage were used for
further assays.
Set-up of a homogenous AlphaLISA assay to measure the
levels of ubiquitylated proteins from cell lysates
The aim was to establish a universal assay to measure
the total amount of ubiquitylated proteins from cells,
under native conditions, in a HTS format and based on
ubiquitin-traps (TUBEs) that specifically capture and
protect ubiquitylated proteins with high affinity. To set
up this biological assay, P. falciparum iRBCs were used
AC
B
Figure 1 Analysis of ubiquitylated proteins along Plasmodium falciparum intra-erythrocytic cycle. A. Schematic representation of the parasite cycle in
blood stages. It starts when merozoites invade uRBC resulting in the first phase called ring stage. After 24 hrs, the parasite enters in a phase with high
metabolic activity, the trophozoite. A few hours later, at the schizont stage, the parasite produces merozoites that will rupture the RBC membrane,
looking for new uRBCs to invade and start a new cycle. B. Western blot analysis with P4D1 antibody shows basal levels of ubiquitylated proteins in
rings, trophozoites and schizonts. C. Effect of proteasome inhibitors MG132 (1.15 μM) and epoxomicin (0.26 μM), on the levels of ubiquitylated proteins
from rings, trophozoites and schizonts. Atovaquone at 0.02 μM was used as negative control.
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haemoglobin present in the host cells.
Initially, the TR-FRET technology was tested using
many combinations of tagged-TUBEs, antibodies and
fluorophores but results were not successful, maybe due
to the large distance between the fluorophore pair. Differ-
ent combinations of antibodies, beads and tagged TUBEs
were also tested using the AlphaLISA technology, which
enables the detection of larger complexes than TR-FRET.
Only one combination among tens tested was successful,
which is indicated in Figure 2A. All these failed attempts
reflect the difficulty of establishing this method to detect
levels of ubiquitylated proteins in cell lysates, with the
added difficulty of the presence of interfering haemoglo-
bin. Glutathione present on AlphaLISA acceptor beads
recognizes the GST-tag of the TUBEs, which tightly inter-
act with ubiquitylated proteins present in cell extracts.
These ubiquitin moieties covalently linked to the proteins
are also recognized by the ubiquitin antibody FK2. Protein
A AlphaLISA donor beads bind to Fc domain of this anti-ubiquitin antibody. Therefore, only in presence of ubiqui-
tylated proteins of the extracts AlphaLISA beads are close
enough to enable the energy transfer. The excitation of
the protein A donor beads by a laser beam at 680 nm pro-
duces the release and diffusion of singlet oxygen mole-
cules that react with a thioxene derivative in the acceptor
beads, generating chemiluminescence at 370 nm. This re-
action further activates fluorophores present on the same
bead that subsequently emit light, which can be detected
at 615 nm. The signal emitted by the acceptor beads is
proportional to the amount of polyubiquitin chains
present in the cells. Singlet oxygen falls to the ground
state and no signal is produced in absence of the complex.
In order to determine the optimal amount of each
component, proteins from cell extracts, TUBEs, anti-
body, and beads were titrated, keeping all other compo-
nents fixed. BSA (0.1%) was added to the AlphaLISA
assay buffer and Triton X-100 to the lysis buffer to de-
crease the non-specific binding. DTT (1.5 mM) was also
added to keep the glutathione reduced and optimize
A B
Figure 2 Schematic representation of the developed assays A. TUBE-AlphaLISA assay. Ubiquitylated proteins from cell lysates are captured by the
GST-TUBE trap during the lysis. The GST-TUBEs trap binds to GSH AlphaLISA acceptor beads. FK2 antibody recognizes and binds to ubiquitin
chains covalently attached to substrates and it is recognized by the protein A AlphaLISA donor bead. AlphaLISA donor bead is excited at 680 nm
releasing singlet oxygen that diffuses towards the acceptor bead. After excitation acceptor bead emits light at 615 nm. B. Schematic representation
of TUBE-DELFIA assay. P. falciparum iRBCs are lysed in presence of biotin-TUBEs attached to streptavidin coated plates. Ubiquitylated proteins from
cell lysates captured by the TUBEs ubiquitin traps are then immunodetected by the anti-ubiquitin FK2 mouse antibody which is recognized by a
secondary antimouse antibody labeled with europium. The addition of the enhancement solution causes the release of the europium generating
signal at 615 nm. Washes are required before each incubation step to remove unbound proteins/reagents.
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ences coming from the haemoglobin present in RBCs,
during the assay development the source of ubiquity-
lated proteins came from isolated and lysed P. falcip-
arum parasites (see Methods, “Purification of iRBCs
with schizonts and treatment with compounds”). The
determination of the optimal amount for each reagent is
shown in Figure 3. Figure 3A shows a cross-titration of
TUBEs and P. falciparum cell extracts. Beads concentra-
tion was fixed at 10 μg/mL and FK2 antibody was used
at 1:200. Signal was normalized with respect to the basal
level obtained in each condition. No signal was detected
in absence of TUBEs or P. falciparum cell extracts.
AlphaLISA counts were directly dependent on both
components as expected, reaching a maximum at the
optimal concentration of 100 ng of TUBEs. Plasmodiumfalciparum cell extracts at 1.3 μg/well were chosen for
subsequent assays because at this concentration the sys-
tem is able to detect both increased or decreased
amounts of ubiquitylated proteins within the linear
range (0.4-4 μg/well). Figure 3B shows the concentration
curve for TUBEs at fixed amount of 1.3 μg of P. falcip-
arum cell extracts. Beyond the optimal concentrations
stated before, a decrease in the signal was observed due
to a ‘Hook effect’ , a common phenomenon found in
AlphaLISA assays. The Hook effect occurs when beads
are saturated with analyte. Thus, excess of analyte dis-
rupts associations between donor and acceptor beads,
causing a progressive decrease in the signal.
Next, we studied the effect of the antibody concentra-
tion on the assay using 10 μg/mL of beads and the con-




Figure 3 Optimization of the components of the AlphaLISA assay. Different panels show the titration of all the reagents. X axis of A, B and F
panels are represented in logarithmic scale A. Cross titration of TUBEs and ubiquitylated proteins present in P. falciparum cell extracts, using
10 μg/mL of beads and 1:200 FK2 antibody dilution. Signal is represented as the ratio of AlphaLISA counts in presence an absence of TUBEs. B.
Concentration curve of TUBEs at 1.3 μg of P. falciparum cell extracts. C. Titration of the anti-ubiquitin FK2 antibody with 100 ng TUBEs, 1.3 μg P.
falciparum cell extracts and 10 μg/mL of beads. D. Cross titration of AlphaLISA donor and acceptor beads at conditions previously determined
(100 ng TUBEs, 1:400 FK2 antibody and 1.3 μg of P. falciparum cell extracts). E. Titration of donor beads at 20 μg/mL of acceptor beads. F. iRBCs
with schizonts at 100% parasitaemia and adjusted to different haematocrits with and without treatment of MG132.
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Table 1 Advantages and disadvantages of these new
AlphaLISA and DELFIA assays
Advantages Disadvantages





- Homogeneous: mix and
measure assay eliminating
washing steps
- Save time and work
- 1,536 well plate format
DELFIA • Lower interference: • Lower throughput:
- Compounds and non-
specific assay reagents
are removed in the
washing steps
- Heterogeneous. Washes
are needed: labour intensive
- Transfer step: iRBCs transfer
to streptavidin plates is
required after treatment.
Time consuming.
- More sources of assay
variability
- 384-well plates
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studied. Maximum signal of the system was reached
when antibody was used at the optimal dilution 1:400.
Finally, a titration of AlphaLISA acceptor and donor
beads was performed to determine their optimal concen-
trations (Figure 3D). A Hook effect was observed again,
showing a maximum signal at 20 μg/mL of acceptor
beads for any donor beads concentration. Figure 3E
shows the titration of the donor beads with 20 μg/mL of
acceptor beads. Beads concentration for further experi-
ments was fixed at 20 μg/mL acceptor beads and 40 μg/mL
donor beads.
As explained above, the optimal concentration of each
component was established using isolated P. falciparum
cell extracts, that is, lysed parasites in which haemoglo-
bin was washed off to avoid interferences in the read-
out. As the final objective was to develop an assay sensi-
tive enough to detect changes in the level of the total
parasite ubiquitylated proteins inside the iRBCs, the
optimum haematocrit (percentage of the volume of
RBCs versus total volume) for P. falciparum iRBCs at
100% parasitaemia was determined, as well as the assay
sensitivity in presence of an UPS inhibitor. Figure 3F
shows iRBCs with schizonts at 100% parasitaemia,
treated for 1 hr with the proteasome inhibitor MG132 at
1.5 μM. These iRBCs prepared at different haematocrits
were added to the plates and then levels of ubiquitylated
proteins were measured with the AlphaLISA assay using
the conditions previously established. A range of haem-
atocrit between 0.2 and 2% generated an acceptable sig-
nal compared to background (ratio of accumulated
ubiquitylated proteins in presence of MG132 versus
basal levels) despite haemoglobin interferences with the
AlphaLISA signal. Thus, haematocrit 0.4% of purified
iRBCs with schizonts was chosen for further AlphaLISA
assays, as this concentration was within the linear range
and allow the detection of an increased amount of pro-
teins in presence of the proteasome inhibitor MG132.
Besides the optimization described above, other critical
protocol settings, such as order of addition, binding, in-
cubation time of antibodies and beads, procedures for
cell lysis in the 384- and 1,536-well plates, temperature
and volume of different components of the assay were
analysed and included in the final protocol described in
Methods. The assay was adapted to 384- and 1,536-well
plate format obtaining a similar signal to background ra-
tio. The 1,536-well format was chosen for future HTS
campaigns whose results will be published elsewhere.
Heterogeneous DELFIA assay to measure the levels of
ubiquitylated proteins from cell extracts
AlphaLISA technology is quite similar to an enzyme-
linked immunosorbent assay (ELISA). It is a selective,
sensitive and versatile technique and has the additionaladvantage that it allows performing assays in high-
throughput format since washing steps are not required.
However, the absence of washing steps also favours in-
terferences that can appear in the screening of large col-
lections of compounds, producing false positive or
negative signals. A confirmatory assay to measure the
levels of ubiquitylated proteins is desirable to identify
possible interferences of the previous AlphaLISA assay
or if high throughput is not required. Therefore, an or-
thogonal ubiquitin ELISA assay based on TUBEs and
DELFIA technology has been established. DELFIA assay
is a heterogeneous method that requires washing steps
after each addition to remove unbound reagents. Advan-
tages and disadvantages of these AlphaLISA and DEL-
FIA assays are reflected in Table 1.
DELFIA assay was developed using biotin-tagged
TUBEs to anchor ubiquitin-traps to the 384-well,
streptavidin-coated plates. After treatment with the
compounds, cells are plated and lysed in the presence of
TUBEs, which recognizes ubiquitylated proteins with
high affinity and prevents proteasome-mediated prote-
olysis or DUB-mediated deconjugation processes. Anti-
ubiquitin FK2 antibody binds ubiquitylated proteins and
it is recognized by an anti-mouse DELFIA antibody la-
belled with europium (Figure 2B). This DELFIA sand-
wich is then treated with enhancement solution to
release europium from the secondary antibody, produ-
cing signal at 615 nm that is proportional to the amount
of ubiquitylated proteins present in the well.
Each component of the assay was optimized in a simi-
lar way as described for AlphaLISA assay (Figure 4). The
first component evaluated was the biotin-TUBEs, which
were titrated-fixing concentrations for primary and sec-
ondary antibodies at 1:200 in absence or presence of



















































Figure 4 Optimization of the components of the TUBE-DELFIA assay. X axis of panels A and C are represented in logarithmic scale. A. Titration of
TUBEs with saturating concentration of proteins from isolated P. falciparum cell extracts (10 μg), using anti-ubiquitin FK2 and europium antibodies
at 1:200 dilution. B. TUBE-DELFIA assay using a saturating concentration of proteins from isolated P. falciparum cell extracts (10 μg), 30 ng TUBEs
and three different concentrations of anti-ubiquitin FK2 and secondary europium antibodies. A control without proteins was used to determine
the background signal. C. Haematocrit titration of iRBCs with schizonts at 100% parasitaemia treated with MG132 inhibitor (1.5 μM), using the
conditions previously established (30 ng TUBEs, 1:100 FK2 and 1:200 europium antibodies).
Mata-Cantero et al. Malaria Journal  (2015) 14:200 Page 10 of 16saturating concentration of proteins from isolated P. fal-
ciparum cell extracts (10 μg). BSA (0.1%) was also added
to the antibody solutions to decrease the non-specific
binding. Saturation of the streptavidin-coated well was
reached at 30 ng of biotin-TUBEs. This amount of
biotin-TUBEs was used in subsequent experiments as
concentrations higher than 60 ng produced a decrease
in the signal which was specific and dependent. Signal
was specific and dependent on the presence of TUBEs
and ubiquitylated proteins because no changes in signal
were observed in the absence of cell extracts (Figure 4A).
In order to determine the optimal dilution of primary
and secondary antibodies, they were crosstitrated using
three different dilutions. The assay was also performed inthe absence of P. falciparum proteins to estimate the
background signal. Dilutions 1:200 of europium antibody
and 1:100 of FK2 primary antibody were chosen for fur-
ther set up experiments as they produced the highest sig-
nal to background ratio (Figure 4B).
Once TUBEs and antibody dilutions were optimized,
the haematocrit of the culture that displayed the max-
imum signal was established by testing different amounts
of P. falciparum iRBCs at 100% parasitaemia (Figure 4C).
Cultures at different haematocrits were treated for 1 hr
with the proteasome inhibitor MG132 (1.5 μM) to allow
the maximal accumulation of ubiquitylated proteins and
saturation of TUBEs. Treatment was performed in an-
other plate to avoid interferences with the streptavidin-
Mata-Cantero et al. Malaria Journal  (2015) 14:200 Page 11 of 16coated plates. After the incubation with the inhibitor,
iRBCs were transferred to the streptavidin plate previously
coated with biotin-TUBEs. Maximal signal was observed
with 0.2% haematocrit. Concentrations above 0.2% did not
produce changes in the signal because of saturation of the
TUBE binding sites.
Pharmacological validation of AlphaLISA and DELFIA
assays using known proteasome inhibitors
Assays developed in HTS format for drug discovery
should first be validated for biological and pharmaco-
logical relevance but also for assay performance. Seven
different proteasome inhibitors, known to inhibit the
growth of P. falciparum cells [14], were tested at differ-
ent concentrations in both assays to verify that they pro-
duced an accumulation of ubiquitylated proteins and
that the assays were sensitive enough to detect this in-
crement in a robust manner. iRBCs with P. falciparum
schizonts at 100% parasitaemia were obtained as de-
scribed in Methods and treated for 1 hr with com-
pounds. Dose–response experiments were performed
starting at different concentrations according to the re-
ported IC50 of each compound [14]. For representation
purposes, compound effects have been normalized be-
tween 0 and 100% inhibition, the maximum (100%) be-
ing the highest amount of accumulated ubiquitylated
proteins for each inhibitor and the minimum (0%) being
the basal level of ubiquitylated proteins without inhibitor
(Figure 5A).
Proteasome inhibition caused by the compounds
tested, led to an accumulation of P. falciparum ubiquity-
lated proteins in a dose-dependent manner. Bell effect
was observed with some compounds at the highest con-
centrations tested, but it was not related with the satur-
ation of the assay components (Hook effect) as it was
observed at different levels of maximum response. This
effect could be due to the biological mode of action of
the compound. Point of curve showing this effect was
not included in the IC50 fitting. Assays with uRBCs at
the same haematocrit were performed in parallel to con-
firm that observed changes in ubiquitylated protein
levels occurred in the parasite and not in the host. No
significant changes were observed in the presence of
proteasome inhibitors, as the host proteasome is not
very active.
The intrinsic variability of the assay is reflected in the
different maximal responses obtained with these tool
compounds in different replicates that correspond to dif-
ferent days (Table 2), although this fact did not affect the
pIC50 values (Figure 5B). Maximum stimulation reached
for each compound was in the range of 1.3-2.7-fold
(Table 2) regarding basal levels. Factors contributing to
this intrinsic variability could be due to synchronization
and purification steps of the cells as well as the parasitebiology. Results also indicate that a compound with a
pIC50 between 5.6-8.2 in whole cell, acting upon the UPS,
can be picked up with these two assays.
The correlation of pIC50s from both assays is shown
in Figure 5B. pIC50 is the negative logarithm of the con-
centration in molar units that produces the 50% of the
biological response (pIC50 = −log [IC50]), in this case,
the increase of ubiquitylated proteins. The inter-assay
accuracy, which is the measure of the deviation of the
assay average from one assay to the other under perfect
match conditions, as well as the precision (Pearson’s cor-
relation), was estimated for each assay. Thus, the con-
cordance correlation coefficient (CCC) that takes into
account both parameters (CCC = interassay precision ×
interassay accuracy) was calculated for DELFIA vs
AlphaLISA assays, obtaining a value of 0.93, which
means that the match between both assays is perfect.
Assays with values of CCC greater than 0.81 are consid-
ered identical (perfect match) as CCC is the product of
two correlation values.
pIC50 average of the compounds in both assays was
also compared with the reported pIC50 that led to the
parasite growth inhibition in the whole cell assay [14]
(Figure 5C and Table 2). The pIC50 of bortezomib in
whole-cell assay is the average of the pIC50 previously
reported [13,14] as both published data differ in 0.91 log
units. The CCC obtained was 0.82, which is a perfect
match even when pIC50s were obtained with one hour
of compound incubation, while the whole-cell assay re-
quires at least 48 hours of incubation (Figure 5C).
These results strongly suggest that the UPS is the pri-
mary target of these compounds and that the parasite
death is due to its deregulation. It confirms the rele-
vance of the UPS as a drug target for malaria treatment
and also validates these AlphaLISA and DELFIA assays
to detect UPS inhibitors in HTS conditions.
Assay robustness
The suitability of both assays to carry out HTS cam-
paigns was determined with previously tested prote-
asome inhibitors scattered in known positions within the
plates (spike plates) to simulate a real HTS compound
plate. They were placed at four different concentrations:
a) the maximum concentration of each curve in dose re-
sponse assays (Figure 5A); b) three times the reported
IC50 (whole cell); c) the reported IC50 (whole cell); and,
d) a non-inhibitory concentration. In Figure 6A, size of
the points for each compound is proportional to the
concentration tested (see embedded Table). Bigger sym-
bols indicate higher concentrations. The level of ubiqui-
tylated proteins present in P. falciparum iRBCs with
schizonts was calculated as a percentage of stimulation
compared with ubiquitylated protein basal levels (control
1 without any treatment), which corresponds to 100% of
AB C
Figure 5 Correlation between AlphaLISA and DELFIA assays. A. Dose–response curves of known proteasome inhibitors in TUBE-AlphaLISA (left
panel) and TUBE-DELFIA assays (right panel). The response is represented as a percentage of inhibition, which is calculated normalizing the data
to the maximal signal obtained for each compound (see data analysis section). B. Correlation of pIC50s in TUBE-AlphaLISA and TUBE-DELFIA
assays (average of at least 2 copies). Each point corresponds to a particular proteasome inhibitor. Interassay accuracy, Pearson’s correlation and
CCC (the multiplication of both values) are shown. Grey line represents perfect correlation (y = x) while black doted lines are the perfect correlation ± 1
log unit (y = x ± 1). C. Correlation of the average of pIC50 obtained in the AlphaLISA and DELFIA assays vs reported pIC50 that produce the parasite
growth inhibition in the whole cell assay.
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using two known proteasome inhibitors, MG132
(1.5 μM) or lactacystin (15 μM), was also included for
internal reference. Both caused similar stimulation levels
(calculated as an average of all points with either of these
two inhibitors). Compounds whose response was above
the statistical cut-off (calculated as the average of thecontrol 1 population plus three times the standard devi-
ation), which is around 30%, were considered as positive
in the assays. Some compounds showed the previously
mentioned bell effect, such as gliotoxin and lactacystin in
DELFIA assay, and also clasto-lactacystin-β-lactone and
MG132 in AlphaLISA assay (Figure 6A). Despite that, re-
sults indicate that it is possible to find inhibitors in a
Table 2 pIC50 and maximum percentage of stimulation of proteasome inhibitors in different assays










Epoxomicin 8.17 7.64 ± 0.09 178 ± 47 7.74 ± 0.24 177 ± 15
Bortezomib 7.05 7.95 ± 0.08 178 ± 24 8.16 ± 0.05 180 ± 14
Gliotoxin 5.66 5.88 ± 0.73 217 ± 53 6.12 ± 0.27 180 ± 26
MG132 7.65 7.17 ± 0.04 236 ± 36 7.41 ± 0.21 189 ± 55
MG115 7.01 6.88 ± 0.09 208 ± 22 6.92 ± 0.21 185 ± 17
Lactacystin 5.83 5.81 ± 0.07 217 ± 27 6.06 ± 0.22 193 ± 32
Clasto-lactacystin β lactone 5.83 6.30 ± 0.09 195 ± 19 6.48 ± 0.18 198 ± 17
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percentage of stimulation of all the compounds is above
the statistical cut-off at that concentration.
Percentage of stimulation of iRBCs treated with the
proteasome inhibitor MG132 or lactacystin (control 2)
as well as of iRBCs without treatment (control 1), is rep-
resented in Figure 6B. These results were obtained from
96 different wells for each control and show that the ro-
bustness of the assays’ performance making them suit-
able for screening campaigns. In Figure 6C bars
represent the robust average of control 1 (basal levels of
ubiquitylated proteins, no treatment), control 2 (cells
treated with MG132 or lactacystin) and a control with-
out P. falciparum cell lysates in both assays. Control 1
was 100% of stimulation while control 2 was around
220% in AlphaLISA and 170% in DELFIA assay. Robust
coefficient of variation (CV), which is calculated with
the formula CV = 100*(robust standard deviation/robust
average), was similar in both assays. CV values were
below 15% in both cases, which is the maximum permis-
sible limit to consider a stimulation assay robust. Due to
the low signal to background obtained with these tool
compounds and the maximal asymptote variability, it is
recommended not to use the control 2 to normalize the
data in a HTS campaign, but to include it as a positive
control of stimulation in all the plates. Signal-to-
background ratio (S/B) between basal levels of ubiquity-
lated proteins and the signal obtained without cell extracts
was 15.3 and 17.4 in AlphaLISA and DELFIA, respect-
ively. Altogether these results confirm that both assays are
able to differentiate levels of ubiquitylated proteins and
that the small window between control 1 and control 2 is
due to small differences of total ubiquitylated proteins in
the presence of proteasome inhibitors (Figure 1C). Despite
that, a screening campaign with both assays is ongoing
and reproducible results are being obtained.
Discussion
After phenotypic screening efforts in the malaria field,
many inhibitors have been found with good in vitro po-
tencies in growth inhibition assays [31-33]. The mode of
action of all these hits is unknown. Assays able todisclose the target or, at least, the pathway they are hit-
ting are urgently needed to focus on novel mechanisms
of action to overcome emerging resistance. For this rea-
son, two universal assays have been developed that are
based on AlphaLISA and DELFIA technologies, coupled
to TUBEs traps, to identify compounds that modify the
activity of the UPS within the cell, as no current anti-
malarial treatment is targeting this pathway. These as-
says are based on the accumulation of ubiquitylated
proteins after compound treatments, making them ideal
for broad applications. The assays could also be applied
to a large diversity of cell lines and pathologies, in
which the UPS plays an essential role, such as cancer,
inflammatory diseases, etc.
Working with 1,536-well plates and RBCs had two
added challenges in the development of the assays. First,
no lysis procedure was previously published in this type
of plate, so a new protocol was set up for this critical
step. And, the second challenge was the presence of hae-
moblogin from the RBC, as its presence interfered with
AlphaLISA assay. Despite this, the S/B with regard to
the sample without RBCs was around 15-fold in Alpha-
LISA assay. This S/B is very similar to that obtained in
DELFIA, where no haemoglobin is present during the
read-out, as it is fully washed away. Both assay formats
have been able to detect changes in the levels of ubiqui-
tylated proteins in presence of different proteasome in-
hibitors, obtaining pIC50s that perfectly correlate with
the known pIC50 that cause parasite growth inhibition
[14]. A short incubation time of just one hour in the as-
says, allows the conclusion that UPS is the primary tar-
get of the tested compounds, the UPS deregulation
being the principal cause of the parasite death.
These AlphaLISA and DELFIA assays can be used in
HTS assay conditions as known proteasome inhibitors
located in random positions in a screening plate have
been detected at different concentrations, all of them be-
ing above the statistical cut-off at 10 μM. Moreover, the
CV of the control was lower than 15% showing their ro-
bustness. AlphaLISA is a more suitable assay to perform
HTS of large compound collections as it has been









Epoxomicin 0.55 0.0204 0.007 0.0003
Bortezomib 20.41 0.756 0.252 0.0093
Gliotoxin 50 6.513 2.17 0.0229
MG132 1.81 0.0672 0.022 0.0008
MG115 7.90 0.2925 0.098 0.0046
Lactacystin 50 4.47 1.49 0.0229




















































































































































Figure 6 Assay robustness and validation. A. Correlation of two plates with proteasome inhibitors located in known positions at four different
concentrations simulating a screening plate (see embedded Table). Response produced by proteasome inhibitors on the levels of ubiquitylated
proteins represented as % of stimulation (% of stimulation = 100*(sample/average control 1). The size of the points is proportional to the
compound concentration tested. Light grey is the linear regression of the data while dark grey is the perfect correlation (y = x). Black dotted lines
represent the statistical cut-off of each replicate (average control 1 + 3*standard deviation). Positive hits are above the cut off. B. Graph of control
1 (iRBCs without treatment), and control 2 (iRBCs with proteasome inhibitor 1.5 μM MG132 or 15 μM lactacystin) in the screening plates (n = 96
wells) represented as % of stimulation. C. Comparison of AlphaLISA (purple) and DELFIA (black) assay control data: robust average in bars, robust
CV in italics and S/B in bold for control 1, control 2 and control without lysates in both assays.
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in dose response, primary hits detected in AlphaLISA
assay. Source of interferences in DELFIA are much
lower than in AlphaLISA because unbound reagents are
removed after washes and compounds are not present
during the binding of the different components.Nonetheless, if a small number of compounds are
screened, TUBE-DELFIA assay can be used as the pri-
mary option.
Since total ubiquitylation is assessed from living cells
cultured in vitro in both assays, all kinds of cell-
penetrating UPS inhibitors or activators that affect
Mata-Cantero et al. Malaria Journal  (2015) 14:200 Page 15 of 16ubiquitylated proteins levels within the cell could be de-
tected. The most obvious compounds could be those
having an effect on the proteasomal activity as it con-
trols a higher number of ubiquitylated proteins than
other components of the UPS. Compounds affecting
DUBs or E3 ligases with a broad spectrum of substrate
proteins could also be identified, being a promising
source of selective compounds [12] However, the major-
ity of E3 ligases and DUBs exhibit substrate specificity
making it more difficult to identify compounds that
affect the levels of ubiquitylation of a small number of
proteins with the assays described. To discover the pre-
cise target, biochemical assays are commercially available
for testing proteasome or DUBs inhibition.
The beauty of this approach is that extensive previous
knowledge about the target pathway is not required to
find inhibitors, as compounds blocking any step of the
UPS that produce a significant variation in the pool of
ubiquitylated proteins can be found. The target decon-
volution of the compounds obtained through this ap-
proach could also lead to identify new druggable targets
within the UPS.
Conclusions
AlphaLISA and DELFIA assays developed here can be
considered as universal systems to assess changes in the
total ubiquitylated protein levels and could be adapted
to detect specific ubiquitylated proteins just by changing
the primary antibody. Here, whole ubiquitilome changes
in P. falciparum have been measured using TUBEs and
anti-ubiquitin FK2 antibody, but this antibody could be
changed for any other against the protein of interest.
Thus, activity of a specific DUB or ligase can be assayed
in HTS campaigns in whole cells and under native con-
ditions without using recombinant proteins or engi-
neered cells. Applications using these assays can be
numerous, not being necessarily related with compound
identification, but with the biology of a certain process
or protein. The quantification of the levels of the specific
components or the whole UPS can also be useful to in-
vestigate the molecular basis of different diseases as they
can be adapted to study any other pathology in which
the UPS plays an essential role, using different cell lines
and/or to measure a specific activity of some of the
components of the UPS in a high throughput format.
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